No evidence higher doses of cholesterol-lowering drug increase risk of acute kidney damage

No evidence higher doses of cholesterol-lowering drug increase risk of acute kidney damage
Credit: University of Otago

New Zealanders taking a higher dose of simvastatin, one of the cholesterol-lowering statin drugs used to prevent heart attacks and strokes, do not appear to have a higher risk of acute kidney damage than those taking a lower dose, according to University of Otago researchers from the Pharmacoepidemiology Research Network.

In the nationwide study just published online in the journal PLOS ONE, the researchers found no relationship between simvastatin dose and the risk of (also known as or ) in the absence of concurrent statin-related serious .

Lead author, Dr Lianne Parkin of the Department of Preventive and Social Medicine, says it was important to undertake this research because previous studies had suggested the risk of acute injury might increase with increasing statin doses.

"But the findings were inconsistent and none of the studies had looked to see whether the acute kidney injury was the result of rhabdomyolysis (a rare adverse effect of statins in which the breakdown of muscle tissue can lead to kidney failure)."

Dr Parkin and colleagues had previously undertaken a national study which found that people taking a higher dose of simvastatin have a greater risk of rhabdomyolysis than people taking a lower dose.

In the latest study, the researchers excluded people whose acute kidney injury was associated with serious muscle damage and then examined the risk of acute kidney injury according to simvastatin dose in two groups of people – those without a history of kidney disease and those with who were not on dialysis.

They found no relationship between simvastatin dose and acute kidney injury in either group.

"This is reassuring", says Dr Parkin, "because statins play an important role in the prevention of major cardiovascular events and they are widely used."

The study was based on anonymised national pharmaceutical dispensing and health data for 340,147 people who started taking simvastatin between January 2006 and December 2013.


Explore further

Serious muscle damage risk from widely used cholesterol lowering drug very low in general population

More information: Lianne Parkin et al. Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study, PLOS ONE (2017). DOI: 10.1371/journal.pone.0182066
Provided by University of Otago
Citation: No evidence higher doses of cholesterol-lowering drug increase risk of acute kidney damage (2017, July 31) retrieved 18 January 2019 from https://medicalxpress.com/news/2017-07-evidence-higher-doses-cholesterol-lowering-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more